GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Institutional Ownership

Summit Therapeutics (LSE:SUMM) Institutional Ownership : 6.22% (As of May. 18, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Summit Therapeutics's institutional ownership is 6.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Summit Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Summit Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


Summit Therapeutics Institutional Ownership Historical Data

The historical data trend for Summit Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Institutional Ownership Chart

Summit Therapeutics Historical Data

The historical data trend for Summit Therapeutics can be seen below:

2019-04-30 2019-05-31 2019-06-30 2019-07-31 2019-08-31 2019-09-30 2019-10-31 2019-11-30 2019-12-31 2020-01-31
Institutional Ownership 6.23 6.24 6.22 6.22 6.22 6.21 6.22 6.22 6.22 6.22

Summit Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Summit Therapeutics (LSE:SUMM) Business Description

Traded in Other Exchanges
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics (LSE:SUMM) Headlines

No Headlines